During the corresponding time, Ataibeckley Inc recorded a revenue increase by 137 % year on year, sequentially revenue grew by 78.62 %. While revenue at the Ataibeckley Inc 's corporate clients
In recent years, mental health disorders have emerged as one of the most significant and challenging global healthcare concerns. Major Depressive Disorder (MDD) affects millions of individuals worldwide, causing debilitating symptoms and diminishing their quality of life. Recognizing the pressing need for innovative solutions, atai Life Sciences, a renowned clinical-stage biopharmaceutical company, has made significant progress in transforming the treatment landscape for MDD. This article provides an extensive update on Beckley Psytech s Phase 1/2a trial of ELE-101 and highlights the initial results from Phase 1, along with the dosing of the first patients in Phase 2a.Addressing the Unmet Needs in MDD Treatm...
Phase 1 Study of BPL-003 Shows Promise in Treating Mental Health Disorders is pleased to present the findings of the Phase 1 study of BPL-003, a novel synthetic intranasal benzoate salt formulation of 5-MeO-DMT, conducted by Beckley Psytech, a subsidiary of atai Life Sciences. This study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BPL-003 in the treatment of mental health disorders.Study Details:The Phase 1 study, recently published in The Journal of Psychopharmacology, involved a randomized, double-blind, placebo-controlled trial with healthy volunteers. The study evaluated the effects of BPL-003 on various parameters, including its safety profile, impact on neural ...
atai Life Sciences, a renowned clinical-stage biopharmaceutical company dedicated to revolutionizing mental health disorder treatments, has recently disclosed encouraging findings from their Phase 1 study involving EMP-01 (R-MDMA). This orally administered drug, derived from the well-known MDMA (3,4-methylenedioxy-methamphetamine), has demonstrated significant potential in addressing mental health disorders. The results offer renewed hope for a breakthrough treatment strategy and signify a potential turning point in the field of mental healthcare.Promising Findings from EMP-01 Phase 1 Study:The Phase 1 study conducted by atai Life Sciences was designed to evaluate the safety and efficacy of EMP-01, specifica...
Sources:
Ataibeckley Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ataibeckley Inc’s corporate clients.
For your research, we’ve provided 9 tables on Ataibeckley Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
37.44 %